Comparison Overview

MACLEODS PHARMACEUTICALS LTD.

VS

Cipla

MACLEODS PHARMACEUTICALS LTD.

304, Atlanta Arcade Marol Church Road, Andheri East, Mumbai, Maharashtra, IN, 400059
Last Update: 2025-12-10
View Profile
Between 750 and 799
https://www.macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 11,522
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Cipla

Lower Parel, Ganpatrao Kadam Marg,, Mumbai, Maharashtra, IN, 400013
Last Update: 2025-12-09
Between 750 and 799
http://www.cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 49,702
Subsidiaries: 7
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/macleods-pharmaceuticals-ltd..jpeg
MACLEODS PHARMACEUTICALS LTD.
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
MACLEODS PHARMACEUTICALS LTD.
100%
Compliance Rate
0/4 Standards Verified
Cipla
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MACLEODS PHARMACEUTICALS LTD. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Cipla in 2025.

Incident History — MACLEODS PHARMACEUTICALS LTD. (X = Date, Y = Severity)

MACLEODS PHARMACEUTICALS LTD. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Cipla (X = Date, Y = Severity)

Cipla cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/macleods-pharmaceuticals-ltd..jpeg
MACLEODS PHARMACEUTICALS LTD.
Incidents

No Incident

https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
Incidents

No Incident

FAQ

Cipla company demonstrates a stronger AI Cybersecurity Score compared to MACLEODS PHARMACEUTICALS LTD. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Cipla company has disclosed a higher number of cyber incidents compared to MACLEODS PHARMACEUTICALS LTD. company.

In the current year, Cipla company and MACLEODS PHARMACEUTICALS LTD. company have not reported any cyber incidents.

Neither Cipla company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing a ransomware attack publicly.

Neither Cipla company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing a data breach publicly.

Neither Cipla company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing targeted cyberattacks publicly.

Neither MACLEODS PHARMACEUTICALS LTD. company nor Cipla company has reported experiencing or disclosing vulnerabilities publicly.

Neither MACLEODS PHARMACEUTICALS LTD. nor Cipla holds any compliance certifications.

Neither company holds any compliance certifications.

Cipla company has more subsidiaries worldwide compared to MACLEODS PHARMACEUTICALS LTD. company.

Cipla company employs more people globally than MACLEODS PHARMACEUTICALS LTD. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither MACLEODS PHARMACEUTICALS LTD. nor Cipla holds SOC 2 Type 1 certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor Cipla holds SOC 2 Type 2 certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor Cipla holds ISO 27001 certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor Cipla holds PCI DSS certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor Cipla holds HIPAA certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor Cipla holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References